Blog
RSS FeedPosted by Michael Wonder on 03 Jul 2022
NHS saves 1.2 billion pounds on medicines over three years
1 July 2022 - The NHS has saved taxpayers £1.2 billion in just three years, while securing cutting-edge treatments for ...
Posted by Michael Wonder on 16 Nov 2021
Are we measuring what matters most on uptake to medicines in England?
16 November 2021 - VPAS is a voluntary agreement between the UK government and the Association of the British Pharmaceutical ...
Posted by Michael Wonder on 14 Feb 2021
Does NICE influence the adoption and uptake of generics in the UK?
14 February 2021 - The aim of this paper is to examine generic competition in the UK, with a special focus ...
Posted by Michael Wonder on 24 Jun 2020
Looking back, UK patients unhappy with adalimumab biosimilar switch
24 June 2020 - The UK results show how challenging switching to a biosimilar can be, according to patient groups. ...
Posted by Michael Wonder on 21 Jan 2020
Achieving cost savings with biosimilars will require new strategies, authors say
20 January 2020 - Improving access to fairly priced, quality-assured generics and biosimilars is essential to realizing the potential public ...
Posted by Michael Wonder on 05 Dec 2019
Is it time to look beyond price with biosimilars?
5 December 2019 - While there is no question that falling prices that come with competition are cause for optimism in ...
Posted by Michael Wonder on 10 Oct 2019
Biosimilars in the UK: where are we now and where does the NHS want to go?
9 October 2019 - The UK health service has well over a decade’s experience of dealing with biosimilars, but the ...
Posted by Michael Wonder on 17 Jul 2019
Majority of patients not asked for consent before being switched to a biosimilar, survey finds
17 July 2019 - The preliminary survey results showed that 52% of patients received a letter from hospital about switching to ...
Posted by Michael Wonder on 05 Jun 2019
NHS publishes update on the use of biosimilars
5 June 2019 - The United Kingdom’s National Health Service (NHS) has published a new document for clinical and nonclinical ...
Posted by Michael Wonder on 23 Oct 2018
Biosimilar adalimumab: a landmark for NHS medicines optimisation
23 October 2018 - The NHS’s bid to improve patient outcomes and save money by switching costly biological drugs for ...
Posted by Michael Wonder on 06 Sep 2018
UK lags behind most of Europe in access to biologics for patients with rheumatoid arthritis
4 September 2018 - Global leader in biosimilars, Celltrion Healthcare announces support for the easing of initiation boundaries for biologics that ...
Posted by Michael Wonder on 02 Aug 2018
NHS saved £324 million by switching to biosimilars and generics
2 August 2018 - The UK’s national healthcare provider saved £324 million by switching its patients to “better value” biosimilar ...
Posted by Michael Wonder on 24 Jul 2018
Prescribing biosimilars
24 July 2018 - Slow adoption is costly. ...
Posted by Michael Wonder on 11 Dec 2017
NHS advises GPs not to prescribe “low value” drugs
30 November 2017 - NHS England will issue guidance to GPs and commissioners to limit the prescribing of “low value” ...
Posted by Michael Wonder on 09 Nov 2017
NICE brings on board Sigma to boost med tech uptake
9 November 2017 - NICE is linking with user experience agency Sigma to develop a new system to improve the ...